about
Early experience with novel immunomodulators for cancer treatmentA phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.The cytokines are comingInterferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis.Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiersImmunomodulating peptides of natural and synthetic origin.Acquired immune deficiency syndrome (AIDS). Progress in drug research and therapeutic potential.Nutrition, immune function, and inflammation: an overview.Immunologic alterations in human immunodeficiency virus infection: a review.Interleukin-2 and granulocyte-macrophage colony-stimulating factor stimulate growth of a virulent strain of Escherichia coli.Cytokines as potential vaccine adjuvants.Immunomodulating drugs: major advances in research and development.Effect of interferon-gamma on the expression of HLA-DR by human melanoma cells of varying metastatic potential.A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.Glycosidase activities in alveolar macrophages from guinea pigs stimulated with a glyco-proteic complex extracted from Klebsiella pneumoniae.
P2860
Q28241744-E223A5B8-B3CC-4497-A876-41C1E6D6C6E9Q33382732-D91E4E27-711F-4225-AF73-092A80DAD8D4Q33867863-8EE478BD-F0D8-46F7-AA89-98217072C1D5Q35625775-63957657-B6E3-43A7-A977-1EFBDB9E3DB8Q36600260-0796A9F3-24B6-4490-9787-B5EF5B538F9BQ37160892-D85F11AD-7544-40F4-B2DE-A1E5A1C9958DQ37639462-BA50BE7F-0F84-4D15-904A-C4A66B5F5593Q37783031-3AAC9B05-CBEB-4419-A23A-4DAB80D04E11Q38243091-75B6A265-C412-40A1-883D-CEB06D5BF417Q38626853-003586E5-CCF6-4E90-80B4-76A467ABDA5DQ40150624-F88ED270-AF4D-415A-AAB8-65E741ED34A8Q40598710-CD83076E-DC65-45B8-BC68-0C0030A60A35Q40841437-74C2EEEC-6AEF-41DC-A4F5-E76E273E7A04Q41723641-319EEE6D-1170-47E5-9C93-518F267C2264Q41749102-0C57648A-62A9-4719-930E-95F1E661311EQ43000510-D6454359-B473-493D-BD72-50F8549DE45EQ54312821-F79C087A-6D64-4900-8B76-241D1AF158E4
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NIH conference. Immunomodulators in clinical medicine.
@en
type
label
NIH conference. Immunomodulators in clinical medicine.
@en
prefLabel
NIH conference. Immunomodulators in clinical medicine.
@en
P2093
P50
P1476
NIH conference. Immunomodulators in clinical medicine.
@en
P2093
Rosenberg SA
Sherwin SA
P304
P356
10.7326/0003-4819-106-3-421
P407
P577
1987-03-01T00:00:00Z